Background: Increasing evidence has suggested that rs2279744 is associated with rs117039649 polymorphism, which can increase the risk of gynecological cancers, including cervical, ovarian, breast, and endometrial cancer. The results are inconsistent so that we performed a meta-analysis of current literature to clarify the impacts of these polymorphisms on gynecological cancer.
Introduction
It is well known that the gynecological cancer is the leading cause of cancer-related death in women. And the major cancer types include cervical cancer (CC), ovarian cancer (OC), endometrial cancer (EC), and breast cancer (BC). The BC is the most common cancer, which can be affected by both environmental and genetic factors. However, the mechanism remains unknown. [1, 2] We thought that BC must have some resemblance in estrogen regulation with the above 3 types. Hence, here we considered it as gynecological cancer to study together [3] . CC is the 3rd-leading cause of death in women' neoplasis worldwide, and the morbidity of CC has increased recently. [4] It has been reported that human papillomavirus is an important cause for CC. [5, 6] OC is most commonly seen among women who died from gynecological malignancies in China, while EC often occurs in well-developed countries and is also influenced by environmental factors. [7] [8] [9] In general, gynecological cancers are threatening the health and lives of women all over the world. However, the therapies for them were absent now. Therefore, further understanding of the mechanism and new method for diagnosis and treatment from genetic perspective are of great significance.
Recent studies have shown that the morbidity of gynecological oncology was controlled by the heredity of genes, [10] and studying on genes to the gynecological oncology is beneficial to analysis the internal mechanism for them. In recent years, the gene fiMDM2 (murine double minute 2), as a proto-oncogene, was found to be an important regulator of P53 through multifarious pathways. [11] Several studies have found that over expression of MDM2 gene can result in excessive inactivation of p53, which can enable damaged cells to escape the cell-cycle checkpoint control and become cancerous. [12, 13] Meanwhile, MDM2 results in the degradation of P53 through E3 ubiquitinligating enzyme, which decreases the function of P53, [14, 15] and leads to the onset and development of various diseases, including cancer. [16, 17] It has been reported that genetic polymorphisms play an important role in gynecological cancer. [18] Research has shown that a T to G change at nucleotide 309 (SNP309) in the first intron of MDM2 gene (rs2279744) increases the affinity of the promoter to the transcription activator Sp1, which leads to the high level of MDM2 mRNA and protein expression that weakens the P53 pathway. [19] It has been reported that MDM2 SNP309 genetic polymorphism could predispose the patient to sporadic cancer risk. [20] For instance, Hong et al [21] found that the MDM2 309GG genotype was associated with an increased risk of esophageal squamous cell carcinoma. Meanwhile, the 309G allele has also been associated with early diagnosis of estrogen receptor-positive BC. [22] In addition, another functional single nucleotide polymorphisms (SNPs) at nucleotide 285 G>C (rs117039649) was also identified in the promoter region located 24 bps from SNP309 in Caucasian, [23] It has been reported that the presence of the 285C allele correlated with a decreased cancer risk for breast, ovarian and EC in patients who harbored 309G allele, [22] which suggested that it may function as a neutralizer to the effect of SNP309 in MDM2.
Several studies reported that the polymorphism of rs2279744 or rs117039649 may be associated with the increased susceptibility to gynecological cancers, and the published articles of metaanalysis nearly included all the types of gynecological cancers, but most of them are single studies, including single type of locus or cancer. [7, 24, 25] None of the articles analyzed the relationship between the polymorphisms of these 2 SNPs and the overall risk of gynecological cancer. In addition, the studies of specific type of cancer also reported conflicting results, such as the analysis of CC by Meissner et al [26] and Roszak et al. [27] The signal path diagram was shown in Fig. 1 .
In our meta-analysis, we aimed to detect the association between rs2279744 or rs117039649 polymorphism and the overall gynecological cancer risk. Meanwhile, the subgroup analysis based on race and cancer types can also help elucidate this association in subgroup of patients and for individual type of cancer.
Materials and methods

Publication research and inclusion criteria
We searched several databases, including PubMed, Embase, Web of science, Springer Link, CNKI and Weipu databases, for genetic association studies of the MDM2 T309G, G285C polymorphisms and gynecological cancer. The keywords used were "MDM2 T309G or MDM2 G285C or rs2279744 or rs117039649" combined with "gynecological cancer or gynecological tumor or gynecology," "GWAS or SNP or polymorphism or allele." All databases were searched from their inception to July, 2016. Only papers published in English or Chinese with English abstract were considered.
Papers are eligible if they meet the following criteria: publication should be a case-control study with all required data elements available, publication evaluated the association between MDM2 T309G or MDM2 G285C polymorphism with the risk of CC, OC, BC, or EC, publication is a human study. The paper screening was conducted independently by 2 investigators. The same criteria were applied when assessed the quality and data extraction of the publications. And publication bias of all articles was analyzed by the funnel plots, Begg test Pr > jtj value >0.05 indicating no publication bias existed. In addition, we have to claim that no ethical approval and patient consent are required in this paper, because all analyses were based on previous published studies in this article, which does not involve using of tissue, blood, urine, genetic material samples and survey scales. 
Quality assessment and data extraction
The quality of the identified studies was assessed according to the New Castle-Ottawa Quality assessment Scale (NOS), which measures the quality of a study based on 10 criteria. Publication with a total score of 8 to 9 points were considered to be highquality, 6 to 7 points were considered moderate quality; and 5 points or lower to be low quality. Two reviewers independently extracted the data using a standard extraction form that includes the following: the first author's name, year of publication; the country of the study, ethnicity of the study subjects, age of the cases and controls, numbers of the cases and controls, cancer type, genotyping methods for MDM2 T309G or MDM2 G285C, and the genotypes' frequency. If a study contained more than 1 cancer type or ethnicity, genotype data were extracted separately according to cancer type or ethnicity for subgroup analysis.
Statistical analysis
We used the goodness-of-fit test to assess the Hardy-Weinberg equilibrium (HWE). Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated for each polymorphism in different genetic models, including recessive genotype, dominant genotype, heterozygous genotype, homozygote genotype, and allele genotype to assess the association between MDM2 T309G or MDM2 G285C polymorphism and the risk of gynecological cancer. Cochran Q test and Higgins (I 2 ) test were used to assess the degree of heterogeneity between studies. The pooled ORs were calculated using a fixed-effects (P > .05 or I 2 < 50%) or random-effects model (P < .05 or I 2 > 50%) based on the level of heterogeneity. The publication bias was also evaluated using the Begg funnel plots (Pr > jzj) and Egger test (Pr > jtj). All data were analyzed using STATA 12.0 software.
Results
Characteristics and quality of the publications
A total of 24 articles were included in this meta-analysis. The selection process was summarized in Fig. 2 , and the characteristics of the 24 studies are showed in Table 1 .
Our analysis included 27 case-control studies (1 article reported the study of 2 ethnicity groups, [26] another reported the study of 3 different types of cancer. [28] ). All studied rs2279744. Of them, 12 studies were conducted among Caucasians, 14 studies were among Asians and 2 in African American. Only 3 papers reported rs117039649, all in Caucasians. The majority of the studies were not deviated from HWE, only 6 showed genetic disequilibrium (P < .05) ( Table 2 ). According to NOS criteria, 2 publications [28, 29] were considered high quality (8 or 9 points), 12 [1, 7, 8, [30] [31] [32] [33] [34] [35] [36] [37] [38] were moderate quality (6 or 7 points), and 10 [2, 11, 20, 26, 27, [39] [40] [41] [42] [43] low quality (5 or lower points) ( Table 3 ).
Analysis of relationship between
SNPs and cancer risk 3.2.1. Association between rs2279744 or rs117039649 polymorphism and gynecological cancer risk. The metaanalysis of rs2279744 polymorphism included 6094 cases and 6808 controls from 27 case-control studies. Three studies Table 1 Characteristics of the studies included in the meta-analysis.
Age, y, mean ± SD, or mean (range) Samples size and type of cancer studied, n
Authors
Year of publication Country Ethnicity Cases Controls Cases Controls Genotyping
Roszak et al [27] 2015 Poland Caucasians 48.3 ± 10.8 47.8 ± 9.5 Cervical 456 481 PCR-RFLP Meissner et al [26] 2007
Brazil Caucasians Negro [7] 2009 China Asian 52.74 ± 10.84 52.69 ± 11.62 Ovarian 257 257 PCR-RFLP Lang et al [2] 2009
Sweden Caucasian 34 30 Breast 123 146 PCR-RFLP Piotrowski et al [30] 2012 Poland Caucasians 59.4 ± 10.2 58.7 ± 10.5 Breast 468 550 PCR-RFLP Wang et al [39] 2013
China Asian --Breast 600 600 PCR-RFLP Koh et al [40] 2011
Singapore Asian 61. [31] 2009 China Asian 52.74 ± 10.84 52.69 ± 11.62 Ovarian 257 257 PCR-RFLP Terry et al [32] 2008 USA Caucasians --Endometrial 122 368 PCR-RFLP Campbell et al [33] 2006 UK Caucasians 40 39 Breast 351 258 PCR-RFLP Walsh et al [20] 2007 USA Caucasians --Endometrial 73 79 PCR-RFLP Cox et al [29] 2007 USA Caucasians 50 50 Breast 306 607 PCR-RFLP Singh et al [42] 2008 India  Caucasians  45  45  Breast  104  105 ARMS-PCR Ashton et al [34] 2009
Australia Caucasians --Endometrial 191 291 PCR-RFLP Ueda et al [28] [8] 2009
Japan Asian --Endometrial 102 95 PCR-RFLP Alshatwi et al [38] 2011
Saudi Asian 50 ± 5 5 0 ± 5 Breast 100 100 TaqMan assay Singhal et al [43] 2012 India Asian --Cervical 182 182 PCR-RFLP Zaja˛c et al [35] [36] 2014 Brazil Negro 37.97 ± 11.69 37.8 ± 10.6 Cervical 293 184 PCR-RFLP Yadav et al [37] 2016 India Asian 48.00 ± 12.51 47.81 ± 11.84 Breast 100 100 AS-PCR ARMS = amplification refractory mutation system, AS = allele specific, PCR = polymerase chain reaction, PIRA = primer introduced restriction analysis, RFLP = restriction fragment length polymorphism, SD = standard deviation.
Zhang com containing 1217 cases and 1215 were included for the analysis of rs117039649 polymorphism. The genotypes of rs2279744 polymorphism are listed in Table 2 . Based on the heterogeneity test (P het < .05), 4 genetic models were analyzed using randomeffect models: TT vs TG + GG, GG vs TG + TT, TT vs GG, and T vs G; and TT vs TG model was analyzed using a fixed-effect model. The ORs for GG vs TG + TT, TT vs GG, and T vs G genetic models were 1.32 (95% CI: 1.11, 1.57, P < .05), 0.77 (95% CI: 0.63, 0.94, P < .05), and 0.86 (95% CI: 0.77, 0.96, P < .05) (Fig. 3A-C) , respectively. The data indicated that TT and Table 2 Genotype and allele distribution of MDM2 polymorphisms in cases and controls.
Roszak et al [27] 
Roszak et al [27] [36] [20] * * * * 4 Cox et al [29] * * * * * * * * 8 Singh et al [42] * * * * * 5 Ashton et al [34] * * * * * * 6 Ueda et al [28] * * * * * * * * 8 Nunobiki et al [8] * * * * * * 6 Alshatwi et al [38] * * * * * * * 7 Singhal et al [43] * * * * 4 Zaja˛c et al [35] For rs117039649 polymorphism, the heterogeneity was insignificant (P het > .05). Thus, the fixed-effects model was used and the pooled ORs for GG vs GC + CC, GC vs GG, and G vs C genetic models were 1.85 (95% CI: 1.32, 2.60, P < .05), 0.55 (95% CI: 0.39, 0.77, P < .05), and 1.83 (95% CI: 1.32, 2.54, P < .05), respectively (Fig. 4A-C) , suggesting that GG or G genotype might be associated with an increased risk of gynecological cancer, compared with GC + CC or C, while GC showed a reduced risk when compared with GG.
Subgroup analysis.
3.2.2.1. The association between rs2279744 and rs117039649 polymorphism and gynecological cancer risk by ethnicity. For rs2279744, all 3 subgroups (Caucasian, Asian, and African American) were analyzed. In Caucasian, 3 genetic models including TT vs TG + GG (OR = 0.89, 95% CI: 0.79, 0.99, P < .05) (Fig. 5A) , TT vs GG (OR = 0.78, 95% CI: 0.63, 0.96, P < .05) (Fig. 5B) , and T vs G (OR = 0.86, 95% CI: 0.75, 0.98, P < .05) (Fig. 5C ) were indicated to be significant, suggesting that TT or T polymorphism may be protective for gynecological cancer. In Asian, an increased risk was observed in the GG vs TG + TT model (OR = 1.36, 95% CI: 1.07, 1.74, P < .05) (Fig. 5D) . However, we did not observe significant association between rs2279744 polymorphism and gynecological cancer risk in African American. These results indicated that rs2279744 polymorphism may be associated with gynecological cancer risk in Caucasian and Asian.
3.2.2.2.
The association between rs2279744 or rs117039649 polymorphism and the types of gynecological cancer. Five genetic models were used to investigate the association between rs2279744 polymorphism and the types of gynecological cancer. Our findings indicated that 3 genetic models, including GG vs TG + TT (OR = 2.02, 95% CI: 1.31, 3.11, P < .05) (Fig. 6A) , TT vs GG (OR = 0.60, 95% CI: 0.43, 0.83, P < .05) (Fig. 6B) , and T vs G (OR = 0.73, 95% CI: 0.56, 0.94, P < .05) (Fig. 6C) , had a significant association with the risk of EC, suggesting that TT or T polymorphism might be associated with a decreased risk of EC. No evidence was observed in relation to other 3 types of cancers. We did not conduct the subgroup analysis because of data limitation. All the data are summarized in Table 4 . 
Publication bias
Funnel plots were symmetric in all genetic models, and Begg test did not show significant publication bias (P > .05) (Fig. 7) , indicating that we random selected the articles with positive and negative outcomes together to a certain extent.
Discussion
It has been reported that Sp1 binding to the MDM2 P2 promoter could be influenced by the polymorphism of SNPT309G, resulting in a high-level expression of MDM2 protein. [19] However, MDM2 SNPG285C allele may play a reverse role to SNP309. [25] The status of 309G is associated with an early diagnosis and tumor formation in Li-Fraumeni syndrome and several malignancies according to recent reports. [44, 45] Interestingly, the association was only observed in women. So we aimed to explore the association between the polymorphisms at these 2 locus and the risk of gynecological cancers in this analysis.
Recently, Xue et al [23] published a meta-analysis of the association between MDM2 T309G polymorphism and EC, but they only studied the SNPT309G with the EC and the analysis was based on the search of 2 databases. In our meta-analysis, we first analyzed the association between SNPs of MDM2 and the risk of gynecological cancer as a whole. Five genetic models were considered including dominant, recessive, homozygote, heterozygous, and allele genotypes. We found that TT and T allele were associated with a reduced risk of gynecological cancer when compared with GG and G allele in SNP309, suggesting that SNPT309G was a risky mutation to women. Meanwhile, SNPG285C performs an opposite role. When compared with GC + CC, an increased risk for gynecological cancer was observed for GG polymorphism, the same was for G vs C. However, GC was associated with a reduced risk of gynecological cancer when compared with GG. Although only 3 articles were included in the analysis of SNPG285C, the number of subjects was still large: 1117 cases and 1221 controls. Hence, the results should be relatively reliable. Interestingly, we also confirmed that SNP309G and 285C, as 2 locus in MDM2 promoter, had an opposing effects in Caucasians regarding the risk of gynecological cancer. One similar point was observed for both SNPs: the GG and G alleles were all associated with increased risk of gynecological cancer when compared with their corresponding variant alleles. In other words, GG or G allele seems play a protective role in these 2 SNPs. We also speculated that patients have a good prognosis when harbor SNP285C even with SNP309G. In summary, we reported the overall effects of SNPT309G/G285C on the risk of gynecological cancers. To our best knowledge, this has not been reported so far. Subgroup analysis was conducted in 2 ways. First, we assessed the association between MDM2 T309G polymorphism and gynecological cancer risk by ethnicity. We found that TT or T allele was associated with a decreased cancer risk in dominate, heterozygote and allele models in Caucasian. While in Asian, compared with TG + TT, GG genotype was associated with a significantly increased risk of gynecological cancer. The results were consistent with our overall analysis. No significant association was found in African American, which may be due to the low number of articles (2 articles). Second, we evaluated the association between MDM2 T309G polymorphism and 4 types of gynecological cancer, respectively. Previous articles of meta-analysis were conducted for breast, cervical, ovarian, and ECs individually. Our study found that GG genotype was associated with an increased risk of endometrial tumor, but not breast tumor, [44, 46, 47] ovarian or cervical tumor. In addition, we found that TT or T allele genotype (compared with GG or G allele) has a significant association with the risk of EC. In a recent report by Xue et al, [24] a significant association between MDM2 T309G polymorphism and EC in the recessive model was identified, which is consistent with our results. However, we also found that SNPT309G is associated with a reduced endometrial risk in TT vs GG and T vs G models ( Fig. 6B and C) . Of note, the results of previous studies were conflicting. Kang et al reported that SNPT390G polymorphism of MDM2 reduced the risk of ovarian tumor in Chinese, [7] while Knappskog et al concluded that the SNP309 G increased the risk of OC. [48] A subsequent meta-analysis [25] also identified a significant association in Asian population. However, in our analysis, we did not find a significant relationship between G allele or GG genotype and ovarian tumor.
BC was common. From our subgroup analysis, we did not find its relationship with SNP309G. One reason may be that the effects may vary by ethnicity. Our analysis has several limitations. Six articles were considered to have HWE disequilibrium, which could have an influence on our results. Only 2 articles included analysis based on African American, which restricted our analysis in this population. The number of reports studied SNP285C polymorphism was small, limits our conclusion in this analysis. More researches are needed in the future, to address the limitations of this analysis.
Conclusion
